Celltrion Pharm, Inc. (068760.KQ)
KRW 61300.0
(-3.01%)
KRW 61300.0
(-3.01%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 162.52 Billion KRW | 1.14% |
| 2022 | 160.69 Billion KRW | -11.23% |
| 2021 | 181.03 Billion KRW | -6.21% |
| 2020 | 193.02 Billion KRW | 19.23% |
| 2019 | 161.88 Billion KRW | 10.14% |
| 2018 | 146.97 Billion KRW | 1.89% |
| 2017 | 144.24 Billion KRW | 3.98% |
| 2016 | 138.73 Billion KRW | -36.0% |
| 2015 | 216.78 Billion KRW | 128438.83% |
| 2014 | 168.65 Million KRW | -8.8% |
| 2013 | 184.93 Million KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 166.24 Billion KRW | 5.71% |
| 2024 Q1 | 157.27 Billion KRW | -3.23% |
| 2023 Q4 | 162.52 Billion KRW | -8.11% |
| 2023 Q1 | 157.46 Billion KRW | -2.01% |
| 2023 Q2 | 166.82 Billion KRW | 5.95% |
| 2023 FY | 162.52 Billion KRW | 1.14% |
| 2023 Q3 | 176.88 Billion KRW | 6.03% |
| 2022 FY | 160.69 Billion KRW | -11.23% |
| 2022 Q3 | 165.44 Billion KRW | -2.58% |
| 2022 Q2 | 169.82 Billion KRW | -4.32% |
| 2022 Q1 | 177.48 Billion KRW | -1.96% |
| 2022 Q4 | 160.69 Billion KRW | -2.87% |
| 2021 Q3 | 184.56 Billion KRW | -1.79% |
| 2021 Q1 | 191.75 Billion KRW | 99458.43% |
| 2021 FY | 181.03 Billion KRW | -6.21% |
| 2021 Q4 | 181.03 Billion KRW | -1.91% |
| 2021 Q2 | 187.92 Billion KRW | -1.99% |
| 2020 FY | 193.02 Billion KRW | 19.23% |
| 2020 Q1 | 166.7 Million KRW | 3.21% |
| 2020 Q2 | 172.37 Million KRW | 3.4% |
| 2020 Q3 | 191.49 Million KRW | 11.09% |
| 2020 Q4 | 192.6 Million KRW | 0.58% |
| 2019 Q3 | 154.37 Million KRW | -4.55% |
| 2019 Q2 | 161.72 Million KRW | 10.67% |
| 2019 FY | 161.88 Billion KRW | 10.14% |
| 2019 Q1 | 146.13 Million KRW | -0.58% |
| 2019 Q4 | 161.52 Million KRW | 4.63% |
| 2018 Q2 | 145.79 Million KRW | 1.82% |
| 2018 Q1 | 143.18 Million KRW | -0.73% |
| 2018 FY | 146.97 Billion KRW | 1.89% |
| 2018 Q4 | 146.97 Million KRW | -5.49% |
| 2018 Q3 | 155.5 Million KRW | 6.67% |
| 2017 FY | 144.24 Billion KRW | 3.98% |
| 2017 Q1 | 134.77 Million KRW | -2.85% |
| 2017 Q3 | 138.15 Million KRW | 1.65% |
| 2017 Q2 | 135.91 Million KRW | 0.85% |
| 2017 Q4 | 144.24 Million KRW | 4.41% |
| 2016 FY | 138.73 Billion KRW | -36.0% |
| 2016 Q2 | 164.54 Million KRW | -11.49% |
| 2016 Q1 | 185.91 Million KRW | -13.89% |
| 2016 Q3 | 169.44 Million KRW | 2.98% |
| 2016 Q4 | 138.73 Million KRW | -18.13% |
| 2015 Q4 | 215.91 Million KRW | 4.0% |
| 2015 FY | 216.78 Billion KRW | 128438.83% |
| 2015 Q1 | 190.78 Million KRW | 13.12% |
| 2015 Q3 | 207.6 Million KRW | 5.71% |
| 2015 Q2 | 196.38 Million KRW | 2.94% |
| 2014 Q1 | 186.23 Million KRW | 0.7% |
| 2014 Q2 | 197.3 Million KRW | 5.95% |
| 2014 Q3 | 199.91 Million KRW | 1.32% |
| 2014 Q4 | 168.65 Million KRW | -15.64% |
| 2014 FY | 168.65 Million KRW | -8.8% |
| 2013 Q3 | 135.47 Million KRW | 11.55% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q2 | 121.44 Million KRW | 0.0% |
| 2013 Q4 | 184.93 Million KRW | 36.51% |
| 2013 FY | 184.93 Million KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 23.72 Billion KRW | -584.97% |
| CMG Pharmaceutical Co., Ltd. | 19.74 Billion KRW | -723.204% |
| Huons Global Co., Ltd. | 254.93 Billion KRW | 36.248% |
| DongKook Pharmaceutical Co., Ltd. | 104.74 Billion KRW | -55.162% |
| Enzychem Lifesciences Corporation | 5.65 Billion KRW | -2773.039% |
| Humedix Co., Ltd. | 2.7 Billion KRW | -5915.652% |
| Boditech Med Inc. | 10.56 Billion KRW | -1437.943% |
| EuBiologics Co., Ltd. | 14.77 Billion KRW | -999.737% |
| FutureChem Co.,Ltd | 3.68 Billion KRW | -4313.464% |
| Huons Co., Ltd. | 124.61 Billion KRW | -30.428% |
| BNC Korea Co., Ltd. | 737.2 Million KRW | -21946.431% |
| AptaBio Therapeutics Inc. | 13.93 Billion KRW | -1066.406% |